|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4439 | |
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Number of the document | 2367553 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09771629.4 |
| Date of filing the European patent application | 2009-12-04 | |
| (97) | Date of publication of the European application | 2011-09-28 |
| (45) | Date of publication and mention of the grant of the patent | 2017-05-03 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2009/066894 |
| Date | 2009-12-04 |
| (87) | Number | WO 2010/065939 |
| Date | 2010-06-10 |
| (30) | Number | Date | Country code |
| 120242 P | 2008-12-05 | US |
| (72) |
FARAG, Sherif, S., US
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY |
| COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY |